Trials / Completed
CompletedNCT00202917
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study the feasibility and Toxicity of allogeneic haploidentical hematopoietic cell transplantation with CD3/CD19 depleted stem cells and a dose reduced conditioning.
Detailed description
Transplantation of a CD3/CD19 depleted stem cell grafts after dose reduced conditioning for the treatment of treatment refractory or relapsed hematologic malignancies after preceding allogeneic or autologous hematopoietic cell transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fludarabine | |
| DRUG | Thiotepa | |
| DRUG | Melphalan | |
| DRUG | OKT-3 | |
| PROCEDURE | CD3/CD19 depletion on CliniMACS |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2009-07-01
- Completion
- 2010-12-01
- First posted
- 2005-09-20
- Last updated
- 2014-05-29
Locations
7 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00202917. Inclusion in this directory is not an endorsement.